The Joint Corp. Reports Fourth Quarter and Full Year 2020 Financial Results
The Joint Corp. (NASDAQ: JYNT) reported robust financial results for Q4 and the full year 2020, with revenue growth of 23% quarterly and 21% annually. Operating income reached a record $5.5 million, a 61% increase from 2019, while Adjusted EBITDA also hit a record at $9.1 million, up 47% year-over-year. The clinic count rose to 579 with 21 new clinics opened in Q4, and franchised licenses sold surged to 56 in the same quarter, compared to 23 in Q4 2019. The company anticipates revenue between $73 million and $77 million for 2021.
- Record operating income of $5.5 million, up 61% from 2019.
- Adjusted EBITDA increased to $9.1 million, a 47% rise compared to 2019.
- Opened 21 new clinics in Q4 2020, totaling 579 clinics by year-end.
- Sold 56 franchise licenses in Q4 2020, compared to 23 in Q4 2019.
- Entered 2021 with projected revenue between $73 million and $77 million.
- None.
- Grows Revenue
- Reports Record Annual Operating Income of
- Posts Record Adjusted EBITDA of
- Increases Total Clinic Count to 579, Opening 21 Clinics in Q4 2020, Compared to 25 in Q4 2019 -
- Sells Record 56 Franchise Licenses in Q4 2020, Up from 23 in Q4 2019 -
SCOTTSDALE, Ariz., March 04, 2021 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, reported its financial results for the quarter and full year ended December 31, 2020.
Financial Highlights: Q4 2020 Compared to Q4 2019
- Increased system-wide sales1 by
24% , to$77.6 million . - Reported system-wide comp sales2 increase of
16% . - Grew revenue
23% to$17.0 million . - Posted record operating income of
$2.8 million , compared to$1.3 million . - Reported record Adjusted EBITDA of
$3.7 million , up from$2.1 million .
Financial Highlights: 2020 Compared to 2019
- Increased system-wide sales1 by
18% , to$260.0 million . - Reported system-wide comp sales2 increase of
9% . - Grew revenue
21% to$58.7 million . - Posted record operating income of
$5.5 million , compared to$3.4 million . - Reported record Adjusted EBITDA of
$9.1 million , up from$6.2 million .
2020 Operating Highlights
- Performed 8.3 million adjustments, up from 7.7 million in 2019.
- Served 1.1 million unique patients, compared to 998,000 in 2019.
- Treated 584,000 new patients, relatively flat compared to 585,000 in 2019.
27% percent of patients who visited had never been to a chiropractor before, up from26% in 2019.- Sold record 56 franchise licenses in Q4, bringing the 2020 total to 121, compared to 126 in 2019.
- Opened 21 new franchised clinics in Q4, bringing the 2020 total to 70, nearly equal to the 71 opened in 2019.
- Increased total clinics to 579 at December 31, 2020, 515 franchised and 64 company-owned or managed, up from 513 at December 31, 2019.
- Repurchased the regional developer (RD) rights in North Carolina on December 31, 2020. Then, repurchased the RD rights for Georgia on January 1, 2021. Combined, the transactions totaled
$2.4 million . As a result, 69 franchised clinics and 37 signed franchise license agreements for unopened clinics shifted from management by RDs to corporate management, thereby eliminating the RD sales commissions and royalties of3% of gross sales.
“Our operating and financial results for 2020 reflect both the resiliency of our business model throughout the pandemic and the commitment of our clinic staff to care for our patients,” said Peter D. Holt, President and Chief Executive Officer of The Joint Corp. “In adapting to the pandemic, the primary change to our operational practices was to increase sanitization and cleanliness procedures. However, our core concept has remained steadfast. Once again, we increased our productivity, resulting in improved clinic performance and greater company profitability. As a result, our Adjusted EBITDA, positive for the third consecutive year, exceeded our plan and further strengthened our foundation, closing 2020 with a record bottom line.”
“We enter 2021 with reignited growth momentum. We will prioritize franchised clinic and greenfield clinic openings as we accelerate growth and drive toward our goal of 1,000 clinics opened by the end of 2023,” concluded Holt.
Financial Results for the Three Months Ended December 31: 2020 Compared to 2019
Revenue was
Selling and marketing expenses were
Operating income was
Adjusted EBITDA was also a record for the company at
Financial Results for the Full Year Ended December 31: 2020 Compared to 2019
Revenue was
Operating income was
Adjusted EBITDA was
Balance Sheet Liquidity
Unrestricted cash was
2021 Guidance for Financial Results and Clinic Openings
Management provided full year 2021 guidance and expects the following:
- Revenue to be between
$73 million and$77 million , compared to$58.7 million in 2020. - Adjusted EBITDA to be between
$10.5 million and$12.0 million , compared to$9.1 million in 2020. - Franchised clinic openings to be between 80 and 100, compared to 70 in 2020.
- Company-owned or managed clinics, through a combination of both greenfields and buybacks, to increases between 20 and 30, compared to 4 in 2020.
Conference Call
The Joint Corp. management will host a conference call at 5 p.m. ET on Thursday, March 4, 2021, to discuss the fourth quarter and year-end 2020 results. To gain immediate access to the call, bypass the operator and avoid the queue, you may preregister by clicking here. Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. Those who prefer to call-in directly may do so approximately 20 minutes prior to the start time by dialing 706-643-5902 or 888-869-1189 and using reference code 8161418. The accompanying slide presentation will be in the IR section of the website under Presentations and in Events. A live webcast of the conference call will also be available on the IR section of the company’s website at https://ir.thejoint.com/events. An audio replay will be available two hours after the conclusion of the call through March 11, 2021. The replay can be accessed by dialing 404-537-3406 or 855-859-2056. The passcode for the replay is 8161418.
Non-GAAP Financial Information
This release includes a presentation of non-GAAP financial measures. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.
EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company’s underlying operating performance and operating trends. Reconciliation of net income/(loss) to EBITDA and Adjusted EBITDA is presented in the table below. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase gain, net (gain)/loss on disposition or impairment, and stock-based compensation expenses. The company defines EBITDA as net income before net interest, tax expense, depreciation, and amortization expenses.
EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company’s financial statements filed with the SEC.
Forward-Looking Statements
This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, the continuing impact of the COVID-19 outbreak on the economy and our operations (including temporary clinic closures, shortened business hours and reduced patient demand), our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, and the other factors described in “Risk Factors” in our Annual Report on Form 10-K as filed with the SEC for the year ended December 31, 2019, as updated or revised for any material changes described in any subsequently-filed Quarterly Reports on Form 10-Q or other SEC filings, and in our Annual Report on Form 10-K for the year ended December 31, 2020 expected to be filed with the SEC on or around March 5, 2021. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.
About The Joint Corp. (NASDAQ: JYNT)
The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, the company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. With nearly 600 locations nationwide and over eight million patient visits annually, The Joint is a key leader in the chiropractic industry. Named on Franchise Times “Top 200+ Franchises” and Entrepreneur’s “Franchise 500®” lists, The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.
Business Structure
The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.
Media Contact: Margie Wojciechowski, The Joint Corp., margie.wojciechowski@thejoint.com
Investor Contact: Kirsten Chapman, LHA Investor Relations, 415-433-3777, thejoint@lhai.com
– Financial Tables Follow –
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES | |||||||
CONSOLIDATED BALANCE SHEETS | |||||||
December 31, | December 31, | ||||||
2020 | 2019 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 20,554,258 | $ | 8,455,989 | |||
Restricted cash | 265,371 | 185,888 | |||||
Accounts receivable, net | 1,850,499 | 2,645,085 | |||||
Notes receivable, net | - | 128,724 | |||||
Deferred franchise and regional development costs, current portion | 897,551 | 765,508 | |||||
Prepaid expenses and other current assets | 1,566,025 | 1,122,478 | |||||
Total current assets | 25,133,704 | 13,303,672 | |||||
Property and equipment, net | 8,747,369 | 6,581,588 | |||||
Operating lease right-of-use asset | 11,581,435 | 12,486,672 | |||||
Deferred franchise and regional development costs, net of current portion | 4,340,756 | 3,627,225 | |||||
Intangible assets, net | 2,865,006 | 3,219,791 | |||||
Goodwill | 4,625,604 | 4,150,461 | |||||
Deferred tax assets | 8,007,633 | - | |||||
Deposits and other assets | 431,336 | 336,258 | |||||
Total assets | $ | 65,732,843 | $ | 43,705,667 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 1,561,648 | $ | 1,525,838 | |||
Accrued expenses | 770,221 | 216,814 | |||||
Co-op funds liability | 248,468 | 185,889 | |||||
Payroll liabilities | 2,776,036 | 2,844,107 | |||||
Operating lease liability, current portion | 2,918,140 | 2,313,109 | |||||
Finance lease liability, current portion | 70,507 | 24,253 | |||||
Deferred franchise and regional development fee revenue, current portion | 3,000,369 | 2,740,954 | |||||
Deferred revenue from company clinics | 3,905,200 | 3,196,664 | |||||
Debt under the Paycheck Protection Program | 2,727,970 | - | |||||
Other current liabilities | 707,085 | 518,686 | |||||
Total current liabilities | 18,685,644 | 13,566,314 | |||||
Operating lease liability, net of current portion | 10,632,672 | 11,901,040 | |||||
Finance lease liability, net of current portion | 132,469 | 34,398 | |||||
Debt under the Credit Agreement | 2,000,000 | - | |||||
Deferred franchise and regional development fee revenue, net of current portion | 13,503,745 | 12,366,322 | |||||
Deferred tax liability | - | 89,863 | |||||
Other liabilities | 27,230 | 27,230 | |||||
Total liabilities | 44,981,760 | 37,985,167 | |||||
Commitments and contingencies | |||||||
Stockholders' equity: | |||||||
Series A preferred stock, | - | - | |||||
Common stock, | 14,174 | 13,899 | |||||
Additional paid-in capital | 41,350,001 | 39,454,937 | |||||
Treasury stock 17,167 shares as of December 31, 2020 and 15,762 shares as of December 31, 2019, at cost | (143,111 | ) | (111,041 | ) | |||
Accumulated deficit | (20,470,081 | ) | (33,637,395 | ) | |||
Total The Joint Corp. stockholders' equity | 20,750,983 | 5,720,400 | |||||
Non-controlling Interest | 100 | 100 | |||||
Total equity | 20,751,083 | 5,720,500 | |||||
Total liabilities and stockholders' equity | $ | 65,732,843 | $ | 43,705,667 | |||
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES | |||||||||||||||
CONSOLIDATED INCOME STATEMENTS | |||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||
December 31, | December 31, | ||||||||||||||
2020 | 2019 | 2020 | 2019 | ||||||||||||
Revenues: | |||||||||||||||
Revenues from company-owned or managed clinics | $ | 9,216,342 | $ | 7,561,644 | $ | 31,771,288 | $ | 25,807,584 | |||||||
Royalty fees | 4,728,476 | 3,819,554 | 15,886,051 | 13,557,170 | |||||||||||
Franchise fees | 544,954 | 385,868 | 2,100,800 | 1,791,545 | |||||||||||
Advertising fund revenue | 1,330,333 | 1,086,479 | 4,506,413 | 3,884,055 | |||||||||||
Software fees | 729,552 | 609,068 | 2,694,520 | 1,865,779 | |||||||||||
Regional developer fees | 232,830 | 209,234 | 876,804 | 803,849 | |||||||||||
Other revenues | 255,657 | 203,322 | 847,100 | 740,918 | |||||||||||
Total revenues | 17,038,144 | 13,875,169 | 58,682,976 | 48,450,900 | |||||||||||
Cost of revenues: | |||||||||||||||
Franchise and regional developer cost of revenues | 1,808,814 | 1,525,381 | 6,090,203 | 5,159,778 | |||||||||||
IT cost of revenues | 132,612 | 108,578 | 417,265 | 406,139 | |||||||||||
Total cost of revenues | 1,941,426 | 1,633,959 | 6,507,468 | 5,565,917 | |||||||||||
Selling and marketing expenses | 2,119,864 | 1,845,124 | 7,804,420 | 6,913,709 | |||||||||||
Depreciation and amortization | 672,525 | 590,742 | 2,734,462 | 1,899,257 | |||||||||||
General and administrative expenses | 9,527,397 | 8,464,787 | 36,195,817 | 30,543,030 | |||||||||||
Total selling, general and administrative expenses | 12,319,786 | 10,900,653 | 46,734,699 | 39,355,996 | |||||||||||
Net loss (gain) on disposition or impairment | 2,092 | (2,423 | ) | (51,321 | ) | 114,352 | |||||||||
Income from operations | 2,774,840 | 1,342,980 | 5,492,130 | 3,414,635 | |||||||||||
Other (expense) income: | |||||||||||||||
Bargain purchase gain | - | - | - | 19,298 | |||||||||||
Other expense, net | (24,230 | ) | (18,046 | ) | (79,478 | ) | (61,515 | ) | |||||||
Total other expense | (24,230 | ) | (18,046 | ) | (79,478 | ) | (42,217 | ) | |||||||
Income before income tax (benefit) expense | 2,750,610 | 1,324,934 | 5,412,652 | 3,372,418 | |||||||||||
Income tax (benefit) expense | (7,882,213 | ) | 33,110 | (7,754,662 | ) | 48,706 | |||||||||
Net income and comprehensive income | $ | 10,632,823 | $ | 1,291,824 | $ | 13,167,314 | $ | 3,323,712 | |||||||
Less: income attributable to the non-controlling interest | $ | - | $ | - | $ | - | $ | - | |||||||
Net income attributable to The Joint Corp. stockholders | $ | 10,632,823 | $ | 1,291,824 | $ | 13,167,314 | $ | 3,323,712 | |||||||
Earnings per share: | |||||||||||||||
Basic earnings per share | $ | 0.75 | $ | 0.09 | $ | 0.94 | $ | 0.24 | |||||||
Diluted earnings per share | $ | 0.72 | $ | 0.09 | $ | 0.90 | $ | 0.23 | |||||||
Basic weighted average shares | 14,108,164 | 13,880,146 | 14,003,708 | 13,819,149 | |||||||||||
Diluted weighted average shares | 14,716,658 | 14,538,338 | 14,582,877 | 14,467,567 | |||||||||||
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
Year Ended | ||||||||
December 31, | ||||||||
2020 | 2019 | |||||||
Net income | $ | 13,167,314 | $ | 3,323,712 | ||||
Adjustments to reconcile net income to net cash provided by operating activities | (4,532,946 | ) | 2,602,799 | |||||
Changes in operating assets and liabilities | 2,548,874 | 1,595,438 | ||||||
Net cash provided by operating activities | 11,183,242 | 7,521,949 | ||||||
Net cash used in investing activities | (4,601,009 | ) | (7,138,062 | ) | ||||
Net cash provided by (used in) financing activities | 5,595,519 | (596,962 | ) | |||||
Net increase (decrease) in cash | $ | 12,177,752 | $ | (213,075 | ) | |||
THE JOINT CORP. AND SUBSIDIARY AND AFFILIATES RECONCILIATION FOR GAAP TO NON-GAAP | |||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||
December 31, | December 31, | ||||||||||||||
Non-GAAP Financial Data: | 2020 | 2019 | 2020 | 2019 | |||||||||||
Net income | $ | 10,632,823 | $ | 1,291,824 | $ | 13,167,314 | $ | 3,323,712 | |||||||
Net interest | 24,230 | 18,046 | 79,478 | 61,515 | |||||||||||
Depreciation and amortization expense | 672,525 | 590,742 | 2,734,462 | 1,899,257 | |||||||||||
Income tax (benefit) expense | (7,882,213 | ) | 33,110 | (7,754,662 | ) | 48,706 | |||||||||
EBITDA | $ | 3,447,365 | $ | 1,933,722 | $ | 8,226,592 | $ | 5,333,190 | |||||||
Stock compensation expense | 207,269 | 183,906 | 885,975 | 720,651 | |||||||||||
Acquisition related expenses | 41,716 | 11,145 | 41,716 | 47,386 | |||||||||||
Bargain purchase gain | - | - | - | (19,298 | ) | ||||||||||
Net loss (gain) on disposition or impairment | 2,092 | (2,423 | ) | (51,321 | ) | 114,352 | |||||||||
Adjusted EBITDA | $ | 3,698,442 | $ | 2,126,350 | $ | 9,102,962 | $ | 6,196,281 | |||||||
___________________
1 System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company’s financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.
2 Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.
FAQ
What were The Joint Corp.'s Q4 2020 revenue figures?
How much did The Joint Corp. earn in Adjusted EBITDA for 2020?
What is The Joint Corp.'s guidance for 2021?
How many clinics did The Joint Corp. open in 2020?